Literature DB >> 29048893

Diastereoselective Synthesis of Functionalized Diketopiperazines through Post-transformational Reactions.

Saeed Balalaie1,2, Reihaneh Ramezani Kejani1, Elmira Ghabraie1, Fatemeh Darvish1, Frank Rominger3, Fatima Hamdan1, Hamid Reza Bijanzadeh4.   

Abstract

A diversity-oriented access to diastereoselective arylidene 2,5-diketopiperazines is elaborated via a sequential Ugi post-transformation involving catalytic cyclization and oxidative Heck reaction sequence. This sequence offers an interesting multicomponent entry to a library of 2,5-diketopiperazines and arylidene 2,5-diketopiperazines under mild reaction conditions in good to excellent yields.

Entities:  

Year:  2017        PMID: 29048893     DOI: 10.1021/acs.joc.7b01855

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  4 in total

Review 1.  The status of isocyanide-based multi-component reactions in Iran (2010-2018).

Authors:  Ronak Afshari; Seyyed Emad Hooshmand; Mohammad Taghi Nazeri; Siamak Javanbakht; Ahmad Shaabani; Reza Mohammadian
Journal:  Mol Divers       Date:  2020-02-18       Impact factor: 2.943

2.  Influence of Open Chain and Cyclic Structure of Peptidomimetics on Antibacterial Activity in E. coli Strains.

Authors:  Parul Sahrawat; Paweł Kowalczyk; Dominik Koszelewski; Mateusz Szymczak; Karol Kramkowski; Aleksandra Wypych; Ryszard Ostaszewski
Journal:  Molecules       Date:  2022-06-06       Impact factor: 4.927

3.  Copper (triazole-5-yl)methanamine complexes onto MCM-41: the synthesis of pyridine-containing pseudopeptides through the 6-endo-dig cyclization of 1,5-enynes.

Authors:  Neda Akbarikalani; Kamran Amiri; Ahmed Al-Harrasi; Saeed Balalaie
Journal:  RSC Adv       Date:  2020-03-12       Impact factor: 4.036

Review 4.  Post-Ugi Cyclization for the Construction of Diverse Heterocyclic Compounds: Recent Updates.

Authors:  Jitender Bariwal; Rupinder Kaur; Leonid G Voskressensky; Erik V Van der Eycken
Journal:  Front Chem       Date:  2018-11-20       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.